Management of primary liver cell carcinoma.
A review of 352 patients with primary liver cell carcinoma treated by the author is presented. The poor rate of resectability (7 per cent) has necessitated various forms of treatment over the years. These are described in detail. Based on this experience, the current form of treatment for nonresectable carcinoma is summarized. Although it is too early to assess this form of treatment, initial results appear to be promising. A second report in the near future is planned.
D000367:Age Factors; D000437:Alcoholism; D001782:Blood Donors; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D003906:Developing Countries; D004932:Esophageal and Gastric Varices / Q000150:complications; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000150:complications; D006498:Hepatectomy; D006499:Hepatic Artery / Q000601:surgery; D006511:Hepatitis B Antigens; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications; D008113:Liver Neoplasms / Q000628:therapy*; D008296:Malaysia; D008297:Male; D009183:Mycotoxins; D009748:Nutrition Disorders; D011379:Prognosis; D044469:Racial Groups; D000509:alpha-Fetoproteins / Q000032:analysis
D006511:Hepatitis B Antigens; D009183:Mycotoxins; D000509:alpha-Fetoproteins